The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
• Robert F. Kennedy Jr. has announced a policy direction to reclassify 14 specific peptides, though the exact regulatory mechanics are still being finalized. • The current challenge is that none of these 14 peptides have undergone the formal FDA approval process, which requires phase 1 through 3 clinical trials and manufacturing validation. • This shift matters because it highlights a gap between how patients typically use these peptides and the rigorous safety and efficacy reviews required for a New Drug Application.
pharmacytimes.com